by Mac Slavo, SHTF Plan:
A little-known virus called the human metapneumovirus, or hMPV has been spreading in the United States. The concerning virus is on the rise and shares symptoms with the flu and colitis, and it is not widely known by the public.
The Centers for Disease Control and Prevention has recent data showing hMPV’s rise this winter and spring. According to recent data published by the CDC, the percent of tests positive for hMPV increased by 19.6 percent for antigen and 10.9 percent for PCR tests at the start of March, when the virus surged this year,
TRUTH LIVES on at https://sgtreport.tv/
According to a 2020 study published in the Lancet Global Health, more than 14 million hMPV infections, 600,000 hospitalizations, and more than 16,000 fatalities occurred in children under the age of five in 2018.
Human metapneumovirus (HMPV) is a commonly found virus that can cause respiratory illness. Although the virus typically has no symptoms in healthy adults, it can cause serious sickness in older adults, those with asthma, babies, and children according to the National Institute of Allergy and Infectious Diseases (NIAID). –Evening Standard
According to the American Lung Association, the majority of hMPV patients experience moderate upper respiratory symptoms resembling a cold. These may consist of a cough, congestion in the nose or runny nose, a sore throat, aches, and fever. This is really just another cold virus the masters are going to attempt to panic the public with. It is nothing more than a brief illness that typically lasts two to five days and resolves on its own. Patients may choose to treat their condition using over-the-counter medications, like a decongestant.
The experts claim that humans will continue to become infected throughout their lifetimes with hMPV since the illness only produces a minimal or ineffective immune response. But don’t worry! The ruling class and big pharma have you covered!
Companies are developing vaccinations to protect against hMPV. According to the website clinicaltrials.gov, Moderna, the manufacturer of the Covid-19 vaccine, has just ended an early trial of an mRNA vaccine against HMPV and parainfluenza.
